J&J rushes drug-resistant TB therapy bedaquiline to FDA
Armed with only a set of mid-stage data on its experimental therapy for drug-resistant TB, J&J's Janssen has tossed its NDA to the FDA in search of an accelerated approval.
In Sweden, between 1984 and 1996, there was a four-fold increase in cases of celiac disease, and the rates then fell as quickly as they rose. A team of Swedish researchers looked at medical records to unpack whether there really was a cause and effect between changes in the vaccination patterns and the spike in disease.
Otsuka cracks tough TB cases with experimental drug
As drug-resistant cases of tuberculosis rage, Otsuka has impressed doctors with a developmental drug that has shown an ability to wipe out strains of the airborne bug that have immunity to existing treatments.
Phase II results of Immune Network's therapeutic tuberculosis vaccine were presented at the Drug Resistance and Persistence in Tuberculosis meeting in Uganda, part of the Keystone Symposia Global Health Series.
TB is the leading cause of death among people with HIV infection, and being able to give people a shot that treats HIV and protects against TB would be a major breakthrough for this vulnerable group of people.
The Bacillus Calmette-Guérin vaccine works in superficial bladder cancer, treating early stage disease and cutting recurrences. Vitamin D is linked with boosting the immune system, so researchers are looking at mice with bladder cancer to see what happens when you combine the two.
TB vaccine in South African trials; blueprint will drive development
A new TB vaccine is expected to complete the first advanced clinical trials in South Africa in 2013.
The current tuberculosis vaccine--bacille Calmette-Guérin (BCG)--has produced varying efficacy rates worldwide, ranging from 0% to 80%. In a new study published in Nature Medicine, however,
Scientists at St. George's, University of London, have found a way to assist the body's immune system against cancer using an old tuberculosis remedy. A vaccine created with the germ Baculillus
In an effort to combat tuberculosis, Aeras and the Oxford-Emergent Tuberculosis Consortium have announced the start of a Phase IIb trial of the MVA85A vaccine. The 1,400-person proof-of-concept study